• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of jnmaLink to Publisher's site
J Natl Med Assoc. Jul 2002; 94(7): 619–627.
PMCID: PMC2594316

The changing pattern of prostate cancer in Nigerians: current status in the southeastern states.

Abstract

This was a ten-year, hospital-based retrospective study for the incidence and clinical pattern of prostate cancer in southeastern Nigeria. Clinical information extracted from the files included the TNM stage, histo-pathological grading, level of prostatic acid phosphatase (PAP), mode of presentation and clinical and biochemical response to intravenous and oral diethylstilboestrol diphosphate (Honvan)/ orchidectomy. There were 145 patients, mean age 66.6 + 9.8 years, giving an incidence of 61.3 per 10(5), with 54% under 70 years. Most patients (81.4%) presented late, with 62% metastatic. Over 98% were adenocarcinomas, 77% of which were moderate to well-differentiated cancers. PAP was elevated in 109 patients (75%), (representing 92% of all advanced tumours), and normal in 36 (25%). Forty-two percent of poorly differentiated cancers had normal levels of PAP. Most patients presented with urinary retention (56%), prostatism (44%), anaemia (41%), recurrent UTI (35%), bone pains (20%), haematuria (18%), backache (16%) and paraplegia (6%). Nearly 79% responded to treatment with lowered PAP levels and improved quality of life, within a mean of 26.3+/-13.8 months (range 5-78); objective 81 (58%), subjective 32 (23%), no response 27 (19%). Among paraplegics, 78% had full, and 22% had partial motor recovery. Patients with poorly differentiated cancers had only a 33% two-year survival rate. This study confirmed an upward, though moderate trend in the incidence of prostate cancer in Nigeria. The use of PAP instead of PSA as the tumor marker, a local diet with high fish content but lower animal fat, and poor hospital access may account for the lower incidence in the southeast. Poor health education may account for the high rate of late presentations.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.5M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Images in this article

Click on the image to see a larger version.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Wingo PA, Tong T, Bolden S. Cancer statistics, 1995. CA Cancer J Clin. 1995 Jan-Feb;45(1):8–30. [PubMed]
  • Lu-Yao GL, Greenberg ER. Changes in prostate cancer incidence and treatment in USA. Lancet. 1994 Jan 29;343(8892):251–254. [PubMed]
  • Bouffioux C. Prostate cancer: to screen or not to screen? Eur Urol. 1997;31 (Suppl 1):2–4. [PubMed]
  • Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin. 2000 Jan-Feb;50(1):7–33. [PubMed]
  • Baquet CR, Horm JW, Gibbs T, Greenwald P. Socioeconomic factors and cancer incidence among blacks and whites. J Natl Cancer Inst. 1991 Apr 17;83(8):551–557. [PubMed]
  • Ross R, Bernstein L, Judd H, Hanisch R, Pike M, Henderson B. Serum testosterone levels in healthy young black and white men. J Natl Cancer Inst. 1986 Jan;76(1):45–48. [PubMed]
  • Nkposong EO, Lawani J. Primary carcinoma of the prostate in Ibadan. West Afr Med J Niger Med Dent Pract. 1973 Dec;22(6):108–111. [PubMed]
  • Ogunbiyi JO, Shittu OB. Increased incidence of prostate cancer in Nigerians. J Natl Med Assoc. 1999 Mar;91(3):159–164. [PMC free article] [PubMed]
  • Osegbe DN. Prostate cancer in Nigerians: facts and nonfacts. J Urol. 1997 Apr;157(4):1340–1343. [PubMed]
  • Lee WR, Giantonio B, Hanks GE. Prostate cancer. Curr Probl Cancer. 1994 Nov-Dec;18(6):295–357. [PubMed]
  • Terry P, Lichtenstein P, Feychting M, Ahlbom A, Wolk A. Fatty fish consumption and risk of prostate cancer. Lancet. 2001 Jun 2;357(9270):1764–1766. [PubMed]
  • Steinberg GD, Carter BS, Beaty TH, Childs B, Walsh PC. Family history and the risk of prostate cancer. Prostate. 1990;17(4):337–347. [PubMed]
  • Fowler JE, Jr, Whitmore WF., Jr The incidence and extent of pelvic lymph node metastases in apparently localized prostatic cancer. Cancer. 1981 Jun 15;47(12):2941–2945. [PubMed]
  • Smith JA, Jr, Seaman JP, Gleidman JB, Middleton RG. Pelvic lymph node metastasis from prostatic cancer: influence of tumor grade and stage in 452 consecutive patients. J Urol. 1983 Aug;130(2):290–292. [PubMed]
  • Danella JF, deKernion JB, Smith RB, Steckel J. The contemporary incidence of lymph node metastases in prostate cancer: implications for laparoscopic lymph node dissection. J Urol. 1993 Jun;149(6):1488–1491. [PubMed]
  • Petros JA, Catalona WJ. Lower incidence of unsuspected lymph node metastases in 521 consecutive patients with clinically localized prostate cancer. J Urol. 1992 Jun;147(6):1574–1575. [PubMed]
  • Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, deKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol. 1994 May;151(5):1283–1290. [PubMed]
  • BELT E, TURNER RD. A study of 229 consecutive cases of total perineal prostatectomy for cancer of the prostate. J Urol. 1957 Jan;77(1):62–77. [PubMed]
  • Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI, Walsh PC. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol. 1993 Jul;150(1):110–114. [PubMed]
  • McNeal JE, Bostwick DG, Kindrachuk RA, Redwine EA, Freiha FS, Stamey TA. Patterns of progression in prostate cancer. Lancet. 1986 Jan 11;1(8472):60–63. [PubMed]
  • Figueiredo AJ, Seeni K, Anson KM, Furtado AJ, Miller RA. Are transrectal ultrasonically guided biopsies required for the accurate diagnosis of carcinoma of the prostate? Can digitally guided systematic biopsies offer an acceptable alternative? Br J Urol. 1995 Aug;76(2):187–191. [PubMed]
  • Oesterling JE, Brendler CB, Epstein JI, Kimball AW, Jr, Walsh PC. Correlation of clinical stage, serum prostatic acid phosphatase and preoperative Gleason grade with final pathological stage in 275 patients with clinically localized adenocarcinoma of the prostate. J Urol. 1987 Jul;138(1):92–98. [PubMed]
  • Bahnson RR, Catalona WJ. Adverse implications of acid phosphatase levels in the upper range of normal. J Urol. 1987 Mar;137(3):427–430. [PubMed]
  • Heller JE. Prostatic acid phosphatase: its current clinical status. J Urol. 1987 Jun;137(6):1091–1103. [PubMed]

Articles from Journal of the National Medical Association are provided here courtesy of National Medical Association

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • Cited in Books
    Cited in Books
    PubMed Central articles cited in books
  • MedGen
    MedGen
    Related information in MedGen
  • PubMed
    PubMed
    PubMed citations for these articles